• 
• 
• 

FDA News and Drug Updates

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

Welcome to the Fourth Annual Oncology Guide to New FDA Approvals

New Indications Approved by the FDA in 2018 for Oncology Drugs

Supportive Care

What an Aging Population Means for Cancer Treatment

Saima Iqbal, Ishmam Khan

Supportive Care Updates from ASCO 2017 Highlighted at New Orleans Summer Cancer Meeting

Meg Barbor, MPH

A Taxing Consequence: Taxane Acute Pain Syndrome

Mark L. Zangardi, PharmD, BCOP

View All Supportive Care Articles

Lung Cancer

Lorbrena (Lorlatinib) Approved for the Treatment of Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

Loretta Fala, Medical Writer

Vizimpro (Dacomitinib) Approved for First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer with EGFR Mutation

Loretta Fala, Medical Writer

April 16, 2019 – FDA Approvals, News & Updates

View All Lung Cancer Articles

Conference Correspondent

Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?

The Importance of Compassion: Perspective From a Lifelong Patient

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

Addressing the Second Victim Phenomenon

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

View All Conference Correspondent Articles

Most Popular Articles

Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation

Web Exclusives - FDA Approvals, News & Updates, In the News

FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma

Web Exclusives - FDA Approvals, News & Updates, In the News, Renal-Cell Carcinoma

Welcome to the Fourth Annual Oncology Guide to New FDA Approvals

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates

FDA Approvals of Novel Brand-Name Prescription Cancer Drugs in 2018

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates